City
Epaper

India likely to have COVID vaccine for children above 2 years by September-October: AIIMS Director

By ANI | Updated: June 23, 2021 21:55 IST

Noting that children usually have a mild disease but there is a need to develop COVID-19 vaccines for them, AIIMS Delhi Director Dr Randeep Guleria has said Bharat Biotech and other companies are doing trials at a very fast pace and hoped that data will lead to approvals so that there is a vaccine for children in the country by September-October.

Open in App

Noting that children usually have a mild disease but there is a need to develop COVID-19 vaccines for them, AIIMS Delhi Director Dr Randeep Guleria has said Bharat Biotech and other companies are doing trials at a very fast pace and hoped that data will lead to approvals so that there is a vaccine for children in the country by September-October.

In an interview with ANI, Dr Guleria said that Covaxin's data for children after completion of phase two or three trials is expected by September-October.

Covaxin is an indigenous vaccine developed by Bharat Biotech in collaboration with ICMR.

"Children usually have the mild disease but we need to develop vaccines for children because if we have to control this pandemic everyone should be vaccinated. Bharat Biotech and other companies are doing trials at a very fast pace as parents have come forward with their children for the trials," he said.

"One is hopeful that trial will be completed early and possibly with follow up of about two-three months, we shall have data by September. Hopefully, by that time, approvals will be there so that by September-October, we'll have vaccines from our country which we can give to children," he added.

Dr Guleria said Bharat Biotech is conducting trials between the age group of 2 to 18 years and "this covers a wide spectrum".

Asked about Zydus Cadila vaccine, he said it is a DNA vaccine, a new platform is being used and "it is something that we should proud of".

He added that it is a platform for which research has not been done in past in the country.

"The data is still being collated and one is hoping that they will be able to submit the data to the DCGI for regulatory approval. It will depend on the company how quickly it is able to collate the data and give it to the regulatory authority," he said.

Asked about Pfizer CEO stating that the company is in the "final stages" of getting approval for its COVID-19 vaccine in India, Dr Guleria said that the firm has been in negotiations for some time and these would have possibly reached the final stage.

"One is hopeful that it should occur because the negotiations with the company is going on for quite some time. I am sure now they are reaching a stage where final sort understanding will be there," he said.

( With inputs from ANI )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Bharat Biotech InternationaldelhiindiaIcmr`delhiDelhi capitalSouth delhi district administrationIndiUk-indiaIto delhi
Open in App

Related Stories

NationalDelhi Shocker: Dispute Between Neighbours Turns Violent in Sultanpuri; Police Rule Out Communal Angle

NationalThree, Including Driver, Apprehended Over Security Breach at Delhi Assembly

NationalSecurity Breach at Delhi Assembly; Unidentified Car Storms Into Premises, Ink Hurled at Speaker’s Vehicle

NationalDelhi Bomb Threat: DU Colleges Receive Threatening Mails, Police Launch Massive Search

MaharashtraRift Within NCP? DY CM Sunetra Pawar’s Solo Delhi Visit Sparks Political Buzz; Parth Pawar Calls Reports ‘Baseless’

National Realted Stories

NationalElection Commission files FIR against Trinamool's Nandigram candidate Pabitra Kar

NationalFICCI urges steps to cut industry risks amid West Asia crisis​

NationalModerate rain likely in Tamil Nadu for next seven days, thunderstorms expected in several regions

NationalUttarakhand CM Dhami attends Gaurav Sainik Samman Samaroh; pays floral tribute to late father

NationalTelangana HC reserves order on Pawan Khera's transit anticipatory bail petition